APO Research
Talk to an analyst

APO RESEARCH · REPORT

Muromonab-CD3

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Muromonab-CD3 Industry Growth and Trends Forecast to 2032

22 December 202593 pages

Choose your research edition.

Industry ResearchMuromonab-CD3 Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Muromonab-CD3 Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Muromonab-CD3 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Muromonab-CD3 Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Muromonab-CD3 Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Muromonab-CD3 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Muromonab-CD3 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Muromonab-CD3 is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Muromonab-CD3 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Muromonab-CD3 include Janssen Pharmaceutica, Wuhan Costan Biotechnology Co., Ltd., Shanghai Hanxiang Biotechnology Co., Ltd., Shaanxi Didu Pharmaceutical Chemical Co., Ltd., Pujian Bio (Wuhan) Technology Co., Ltd., Hubei Shishun Biotechnology Co., Ltd. and Beijing Huamei Huli Biochemical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Muromonab-CD3 market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Muromonab-CD3 market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Muromonab-CD3 market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Muromonab-CD3.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Muromonab-CD3 market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Muromonab-CD3 Market by Company

Janssen Pharmaceutica

Wuhan Costan Biotechnology Co., Ltd.

Shanghai Hanxiang Biotechnology Co., Ltd.

Shaanxi Didu Pharmaceutical Chemical Co., Ltd.

Pujian Bio (Wuhan) Technology Co., Ltd.

Hubei Shishun Biotechnology Co., Ltd.

Beijing Huamei Huli Biochemical Co., Ltd.

Muromonab-CD3 Segment by Type

99% Purity

Purity>95%

Muromonab-CD3 Segment by Application

Ulcerative Colitis

Crohn's Disease

Anti-acute Rejection

Acute Lymphoblastic Leukemia Treatment

Type-1 Diabetes

Muromonab-CD3 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Muromonab-CD3 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Muromonab-CD3 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Muromonab-CD3.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Muromonab-CD3 manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Muromonab-CD3 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 99% Purity Table 2. Major Company of Purity>95% Table 3. Global Muromonab-CD3 Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Muromonab-CD3 Sales by Type (2021-2026) & (k units) Table 5. Global Muromonab-CD3 Sales Market Share in Volume by Type (2021-2026) Table 6. Global Muromonab-CD3 Sales by Type (2021-2026) & (US$ Million) Table 7. Global Muromonab-CD3 Sales Market Share in Value by Type (2021-2026) Table 8. Global Muromonab-CD3 Price by Type (2021-2026) & (US$/unit) Table 9. Global Muromonab-CD3 Sales by Type (2027-2032) & (k units) Table 10. Global Muromonab-CD3 Sales Market Share in Volume by Type (2027-2032) Table 11. Global Muromonab-CD3 Sales by Type (2027-2032) & (US$ Million) Table 12. Global Muromonab-CD3 Sales Market Share in Value by Type (2027-2032) Table 13. Global Muromonab-CD3 Price by Type (2027-2032) & (US$/unit) Table 14. North America Muromonab-CD3 Sales by Type (2021-2026) & (k units) Table 15. North America Muromonab-CD3 Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Muromonab-CD3 Sales by Type (2021-2026) & (k units) Table 17. Europe Muromonab-CD3 Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Muromonab-CD3 Sales by Type (2021-2026) & (k units) Table 19. Asia-Pacific Muromonab-CD3 Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Muromonab-CD3 Sales by Type (2021-2026) & (k units) Table 21. Latin America Muromonab-CD3 Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Muromonab-CD3 Sales by Type (2021-2026) & (k units) Table 23. Middle East and Africa Muromonab-CD3 Sales by Type (2021-2026) & (US$ Million) Table 24. Muromonab-CD3 Industry Trends Table 25. Muromonab-CD3 Industry Drivers Table 26. Muromonab-CD3 Industry Opportunities and Challenges Table 27. Muromonab-CD3 Industry Restraints Table 28. Global Muromonab-CD3 Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Muromonab-CD3 Revenue Market Share by Company (2021-2026) Table 30. Global Muromonab-CD3 Sales by Company (2021-2026) & (k units) Table 31. Global Muromonab-CD3 Sales Share by Company (2021-2026) Table 32. Global Muromonab-CD3 Market Price by Company (2021-2026) & (US$/unit) Table 33. Global Muromonab-CD3 Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Muromonab-CD3 Major Company Production Sites and Headquarters Table 35. Global Muromonab-CD3 Company, Product Type & Application Table 36. Global Muromonab-CD3 Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Muromonab-CD3 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Muromonab-CD3 Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Muromonab-CD3 Sales by Region (2021-2026) & (k units) Table 41. Global Muromonab-CD3 Sales Market Share in Volume by Region (2021-2026) Table 42. Global Muromonab-CD3 Sales by Region (2021-2026) & (US$ Million) Table 43. Global Muromonab-CD3 Sales Market Share in Value by Region (2021-2026) Table 44. Global Muromonab-CD3 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 45. Global Muromonab-CD3 Sales by Region (2027-2032) & (k units) Table 46. Global Muromonab-CD3 Sales Market Share in Volume by Region (2027-2032) Table 47. Global Muromonab-CD3 Sales by Region (2027-2032) & (US$ Million) Table 48. Global Muromonab-CD3 Sales Market Share in Value by Region (2027-2032) Table 49. Global Muromonab-CD3 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 50. Global Muromonab-CD3 Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Muromonab-CD3 Sales by Application (2021-2026) & (k units) Table 52. Global Muromonab-CD3 Sales Market Share in Volume by Application (2021-2026) Table 53. Global Muromonab-CD3 Sales by Application (2021-2026) & (US$ Million) Table 54. Global Muromonab-CD3 Sales Market Share in Value by Application (2021-2026) Table 55. Global Muromonab-CD3 Price by Application (2021-2026) & (US$/unit) Table 56. Global Muromonab-CD3 Sales by Application (2027-2032) & (k units) Table 57. Global Muromonab-CD3 Sales Market Share in Volume by Application (2027-2032) Table 58. Global Muromonab-CD3 Sales by Application (2027-2032) & (US$ Million) Table 59. Global Muromonab-CD3 Sales Market Share in Value by Application (2027-2032) Table 60. Global Muromonab-CD3 Price by Application (2027-2032) & (US$/unit) Table 61. North America Muromonab-CD3 Sales by Application (2021-2026) & (k units) Table 62. North America Muromonab-CD3 Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Muromonab-CD3 Sales by Application (2021-2026) & (k units) Table 64. Europe Muromonab-CD3 Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Muromonab-CD3 Sales by Application (2021-2026) & (k units) Table 66. Asia-Pacific Muromonab-CD3 Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Muromonab-CD3 Sales by Application (2021-2026) & (k units) Table 68. Latin America Muromonab-CD3 Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Muromonab-CD3 Sales by Application (2021-2026) & (k units) Table 70. Middle East and Africa Muromonab-CD3 Sales by Application (2021-2026) & (US$ Million) Table 71. Janssen Pharmaceutica Company Information Table 72. Janssen Pharmaceutica Business Overview Table 73. Janssen Pharmaceutica Muromonab-CD3 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Janssen Pharmaceutica Muromonab-CD3 Product Portfolio Table 75. Janssen Pharmaceutica Recent Development Table 76. Wuhan Costan Biotechnology Co., Ltd. Company Information Table 77. Wuhan Costan Biotechnology Co., Ltd. Business Overview Table 78. Wuhan Costan Biotechnology Co., Ltd. Muromonab-CD3 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Wuhan Costan Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio Table 80. Wuhan Costan Biotechnology Co., Ltd. Recent Development Table 81. Shanghai Hanxiang Biotechnology Co., Ltd. Company Information Table 82. Shanghai Hanxiang Biotechnology Co., Ltd. Business Overview Table 83. Shanghai Hanxiang Biotechnology Co., Ltd. Muromonab-CD3 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Shanghai Hanxiang Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio Table 85. Shanghai Hanxiang Biotechnology Co., Ltd. Recent Development Table 86. Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Company Information Table 87. Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Business Overview Table 88. Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Muromonab-CD3 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Muromonab-CD3 Product Portfolio Table 90. Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Recent Development Table 91. Pujian Bio (Wuhan) Technology Co., Ltd. Company Information Table 92. Pujian Bio (Wuhan) Technology Co., Ltd. Business Overview Table 93. Pujian Bio (Wuhan) Technology Co., Ltd. Muromonab-CD3 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Pujian Bio (Wuhan) Technology Co., Ltd. Muromonab-CD3 Product Portfolio Table 95. Pujian Bio (Wuhan) Technology Co., Ltd. Recent Development Table 96. Hubei Shishun Biotechnology Co., Ltd. Company Information Table 97. Hubei Shishun Biotechnology Co., Ltd. Business Overview Table 98. Hubei Shishun Biotechnology Co., Ltd. Muromonab-CD3 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Hubei Shishun Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio Table 100. Hubei Shishun Biotechnology Co., Ltd. Recent Development Table 101. Beijing Huamei Huli Biochemical Co., Ltd. Company Information Table 102. Beijing Huamei Huli Biochemical Co., Ltd. Business Overview Table 103. Beijing Huamei Huli Biochemical Co., Ltd. Muromonab-CD3 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Beijing Huamei Huli Biochemical Co., Ltd. Muromonab-CD3 Product Portfolio Table 105. Beijing Huamei Huli Biochemical Co., Ltd. Recent Development Table 106. North America Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 107. North America Muromonab-CD3 Sales by Country (2021-2026) & (k units) Table 108. North America Muromonab-CD3 Sales Market Share by Country (2021-2026) Table 109. North America Muromonab-CD3 Sales Forecast by Country (2027-2032) & (k units) Table 110. North America Muromonab-CD3 Sales Market Share Forecast by Country (2027-2032) Table 111. North America Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. North America Muromonab-CD3 Market Size by Country (2021-2026) & (US$ Million) Table 113. North America Muromonab-CD3 Market Share by Country (2021-2026) Table 114. North America Muromonab-CD3 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. North America Muromonab-CD3 Market Share Forecast by Country (2027-2032) Table 116. Europe Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 117. Europe Muromonab-CD3 Sales by Country (2021-2026) & (k units) Table 118. Europe Muromonab-CD3 Sales Market Share by Country (2021-2026) Table 119. Europe Muromonab-CD3 Sales Forecast by Country (2027-2032) & (k units) Table 120. Europe Muromonab-CD3 Sales Market Share Forecast by Country (2027-2032) Table 121. Europe Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Europe Muromonab-CD3 Market Size by Country (2021-2026) & (US$ Million) Table 123. Europe Muromonab-CD3 Market Share by Country (2021-2026) Table 124. Europe Muromonab-CD3 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Europe Muromonab-CD3 Market Share Forecast by Country (2027-2032) Table 126. Asia-Pacific Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 127. Asia-Pacific Muromonab-CD3 Sales by Country (2021-2026) & (k units) Table 128. Asia-Pacific Muromonab-CD3 Sales Market Share by Country (2021-2026) Table 129. Asia-Pacific Muromonab-CD3 Sales Forecast by Country (2027-2032) & (k units) Table 130. Asia-Pacific Muromonab-CD3 Sales Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Muromonab-CD3 Market Size by Country (2021-2026) & (US$ Million) Table 133. Asia-Pacific Muromonab-CD3 Market Share by Country (2021-2026) Table 134. Asia-Pacific Muromonab-CD3 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Asia-Pacific Muromonab-CD3 Market Share Forecast by Country (2027-2032) Table 136. Latin America Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 137. Latin America Muromonab-CD3 Sales by Country (2021-2026) & (k units) Table 138. Latin America Muromonab-CD3 Sales Market Share by Country (2021-2026) Table 139. Latin America Muromonab-CD3 Sales Forecast by Country (2027-2032) & (k units) Table 140. Latin America Muromonab-CD3 Sales Market Share Forecast by Country (2027-2032) Table 141. Latin America Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Latin America Muromonab-CD3 Market Size by Country (2021-2026) & (US$ Million) Table 143. Latin America Muromonab-CD3 Market Share by Country (2021-2026) Table 144. Latin America Muromonab-CD3 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Latin America Muromonab-CD3 Market Share Forecast by Country (2027-2032) Table 146. Middle East and Africa Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 147. Middle East and Africa Muromonab-CD3 Sales by Country (2021-2026) & (k units) Table 148. Middle East and Africa Muromonab-CD3 Sales Market Share by Country (2021-2026) Table 149. Middle East and Africa Muromonab-CD3 Sales Forecast by Country (2027-2032) & (k units) Table 150. Middle East and Africa Muromonab-CD3 Sales Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Muromonab-CD3 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Muromonab-CD3 Market Size by Country (2021-2026) & (US$ Million) Table 153. Middle East and Africa Muromonab-CD3 Market Share by Country (2021-2026) Table 154. Middle East and Africa Muromonab-CD3 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Middle East and Africa Muromonab-CD3 Market Share Forecast by Country (2027-2032) Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Muromonab-CD3 Distributors List Table 159. Muromonab-CD3 Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Muromonab-CD3 Image Figure 2. Global Muromonab-CD3 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Muromonab-CD3 Market Size (2021-2032) & (US$ Million) Figure 4. Global Muromonab-CD3 Sales (2021-2032) & (k units) Figure 5. 99% Purity Image Figure 6. Global 99% Purity Sales YoY Growth (2021-2032) & (k units) Figure 7. Purity>95% Image Figure 8. Global Purity>95% Sales YoY Growth (2021-2032) & (k units) Figure 9. Global Muromonab-CD3 Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Muromonab-CD3 Market Share by Type 2025 VS 2032 Figure 11. North America Muromonab-CD3 Sales Market Share in Volume by Type in 2025 Figure 12. North America Muromonab-CD3 Sales Market Share in Value by Type in 2025 Figure 13. Europe Muromonab-CD3 Sales Market Share in Volume by Type in 2025 Figure 14. Europe Muromonab-CD3 Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Muromonab-CD3 Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Muromonab-CD3 Sales Market Share in Value by Type in 2025 Figure 17. Latin America Muromonab-CD3 Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Muromonab-CD3 Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Muromonab-CD3 Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Muromonab-CD3 Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Muromonab-CD3 Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Ulcerative Colitis Image Figure 24. Global Ulcerative Colitis Sales YoY Growth (2021-2032) & (k units) Figure 25. Crohn's Disease Image Figure 26. Global Crohn's Disease Sales YoY Growth (2021-2032) & (k units) Figure 27. Anti-acute Rejection Image Figure 28. Global Anti-acute Rejection Sales YoY Growth (2021-2032) & (k units) Figure 29. Acute Lymphoblastic Leukemia Treatment Image Figure 30. Global Acute Lymphoblastic Leukemia Treatment Sales YoY Growth (2021-2032) & (k units) Figure 31. Type-1 Diabetes Image Figure 32. Global Type-1 Diabetes Sales YoY Growth (2021-2032) & (k units) Figure 33. Global Muromonab-CD3 Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Muromonab-CD3 Market Share by Application 2025 VS 2032 Figure 35. North America Muromonab-CD3 Sales Market Share in Volume by Application in 2025 Figure 36. North America Muromonab-CD3 Sales Market Share in Value by Application in 2025 Figure 37. Europe Muromonab-CD3 Sales Market Share in Volume by Application in 2025 Figure 38. Europe Muromonab-CD3 Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Muromonab-CD3 Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Muromonab-CD3 Sales Market Share in Value by Application in 2025 Figure 41. Latin America Muromonab-CD3 Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Muromonab-CD3 Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Muromonab-CD3 Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Muromonab-CD3 Sales Market Share in Value by Application in 2025 Figure 45. North America Muromonab-CD3 Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. North America Muromonab-CD3 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Muromonab-CD3 Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Muromonab-CD3 Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Europe Muromonab-CD3 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Muromonab-CD3 Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Muromonab-CD3 Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Asia-Pacific Muromonab-CD3 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Muromonab-CD3 Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Muromonab-CD3 Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Latin America Muromonab-CD3 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Muromonab-CD3 Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Muromonab-CD3 Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Middle East and Africa Muromonab-CD3 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Muromonab-CD3 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Muromonab-CD3 Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Muromonab-CD3 Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Muromonab-CD3 Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • 99% Purity
  • Purity>95%
Applications
  • Ulcerative Colitis
  • Crohn's Disease
  • Anti-acute Rejection
  • Acute Lymphoblastic Leukemia Treatment
  • Type-1 Diabetes
Companies covered
  • Janssen Pharmaceutica
  • Wuhan Costan Biotechnology Co., Ltd.
  • Shanghai Hanxiang Biotechnology Co., Ltd.
  • Shaanxi Didu Pharmaceutical Chemical Co., Ltd.
  • Pujian Bio (Wuhan) Technology Co., Ltd.
  • Hubei Shishun Biotechnology Co., Ltd.
  • Beijing Huamei Huli Biochemical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Muromonab-CD3 Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Muromonab-CD3 Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Muromonab-CD3 Market by Type
  6. 1.3.1 99% Purity
  7. 1.3.2 Purity>95%
  8. 1.4 Global Muromonab-CD3 Market Size by Type
  9. 1.4.1 Global Muromonab-CD3 Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Muromonab-CD3 Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Muromonab-CD3 Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Muromonab-CD3 Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Muromonab-CD3 Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Muromonab-CD3 Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Muromonab-CD3 Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Muromonab-CD3 Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Muromonab-CD3 Industry Trends
  2. 2.2 Muromonab-CD3 Industry Drivers
  3. 2.3 Muromonab-CD3 Industry Opportunities and Challenges
  4. 2.4 Muromonab-CD3 Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Muromonab-CD3 Revenue (2021-2026)
  2. 3.2 Global Top Players by Muromonab-CD3 Sales (2021-2026)
  3. 3.3 Global Top Players by Muromonab-CD3 Price (2021-2026)
  4. 3.4 Global Muromonab-CD3 Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Muromonab-CD3 Major Company Production Sites & Headquarters
  6. 3.6 Global Muromonab-CD3 Company, Product Type & Application
  7. 3.7 Global Muromonab-CD3 Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Muromonab-CD3 Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Muromonab-CD3 Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Muromonab-CD3 Tier 1, Tier 2, and Tier 3
4 Muromonab-CD3 Regional Status and Outlook
  1. 4.1 Global Muromonab-CD3 Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Muromonab-CD3 Historic Market Size by Region
  3. 4.2.1 Global Muromonab-CD3 Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Muromonab-CD3 Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Muromonab-CD3 Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Muromonab-CD3 Forecasted Market Size by Region
  7. 4.3.1 Global Muromonab-CD3 Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Muromonab-CD3 Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Muromonab-CD3 Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Muromonab-CD3 by Application
  1. 5.1 Muromonab-CD3 Market by Application
  2. 5.1.1 Ulcerative Colitis
  3. 5.1.2 Crohn's Disease
  4. 5.1.3 Anti-acute Rejection
  5. 5.1.4 Acute Lymphoblastic Leukemia Treatment
  6. 5.1.5 Type-1 Diabetes
  7. 5.2 Global Muromonab-CD3 Market Size by Application
  8. 5.2.1 Global Muromonab-CD3 Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Muromonab-CD3 Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Muromonab-CD3 Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Muromonab-CD3 Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Muromonab-CD3 Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Muromonab-CD3 Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Muromonab-CD3 Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Muromonab-CD3 Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Janssen Pharmaceutica
  2. 6.1.1 Janssen Pharmaceutica Company Information
  3. 6.1.2 Janssen Pharmaceutica Business Overview
  4. 6.1.3 Janssen Pharmaceutica Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Janssen Pharmaceutica Muromonab-CD3 Product Portfolio
  6. 6.1.5 Janssen Pharmaceutica Recent Developments
  7. 6.2 Wuhan Costan Biotechnology Co., Ltd.
  8. 6.2.1 Wuhan Costan Biotechnology Co., Ltd. Company Information
  9. 6.2.2 Wuhan Costan Biotechnology Co., Ltd. Business Overview
  10. 6.2.3 Wuhan Costan Biotechnology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Wuhan Costan Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio
  12. 6.2.5 Wuhan Costan Biotechnology Co., Ltd. Recent Developments
  13. 6.3 Shanghai Hanxiang Biotechnology Co., Ltd.
  14. 6.3.1 Shanghai Hanxiang Biotechnology Co., Ltd. Company Information
  15. 6.3.2 Shanghai Hanxiang Biotechnology Co., Ltd. Business Overview
  16. 6.3.3 Shanghai Hanxiang Biotechnology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shanghai Hanxiang Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio
  18. 6.3.5 Shanghai Hanxiang Biotechnology Co., Ltd. Recent Developments
  19. 6.4 Shaanxi Didu Pharmaceutical Chemical Co., Ltd.
  20. 6.4.1 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Company Information
  21. 6.4.2 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Business Overview
  22. 6.4.3 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Muromonab-CD3 Product Portfolio
  24. 6.4.5 Shaanxi Didu Pharmaceutical Chemical Co., Ltd. Recent Developments
  25. 6.5 Pujian Bio (Wuhan) Technology Co., Ltd.
  26. 6.5.1 Pujian Bio (Wuhan) Technology Co., Ltd. Company Information
  27. 6.5.2 Pujian Bio (Wuhan) Technology Co., Ltd. Business Overview
  28. 6.5.3 Pujian Bio (Wuhan) Technology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Pujian Bio (Wuhan) Technology Co., Ltd. Muromonab-CD3 Product Portfolio
  30. 6.5.5 Pujian Bio (Wuhan) Technology Co., Ltd. Recent Developments
  31. 6.6 Hubei Shishun Biotechnology Co., Ltd.
  32. 6.6.1 Hubei Shishun Biotechnology Co., Ltd. Company Information
  33. 6.6.2 Hubei Shishun Biotechnology Co., Ltd. Business Overview
  34. 6.6.3 Hubei Shishun Biotechnology Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Hubei Shishun Biotechnology Co., Ltd. Muromonab-CD3 Product Portfolio
  36. 6.6.5 Hubei Shishun Biotechnology Co., Ltd. Recent Developments
  37. 6.7 Beijing Huamei Huli Biochemical Co., Ltd.
  38. 6.7.1 Beijing Huamei Huli Biochemical Co., Ltd. Company Information
  39. 6.7.2 Beijing Huamei Huli Biochemical Co., Ltd. Business Overview
  40. 6.7.3 Beijing Huamei Huli Biochemical Co., Ltd. Muromonab-CD3 Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Beijing Huamei Huli Biochemical Co., Ltd. Muromonab-CD3 Product Portfolio
  42. 6.7.5 Beijing Huamei Huli Biochemical Co., Ltd. Recent Developments
7 North America by Country
  1. 7.1 North America Muromonab-CD3 Sales by Country
  2. 7.1.1 North America Muromonab-CD3 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Muromonab-CD3 Sales by Country (2021-2026)
  4. 7.1.3 North America Muromonab-CD3 Sales Forecast by Country (2027-2032)
  5. 7.2 North America Muromonab-CD3 Market Size by Country
  6. 7.2.1 North America Muromonab-CD3 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Muromonab-CD3 Market Size by Country (2021-2026)
  8. 7.2.3 North America Muromonab-CD3 Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Muromonab-CD3 Sales by Country
  2. 8.1.1 Europe Muromonab-CD3 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Muromonab-CD3 Sales by Country (2021-2026)
  4. 8.1.3 Europe Muromonab-CD3 Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Muromonab-CD3 Market Size by Country
  6. 8.2.1 Europe Muromonab-CD3 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Muromonab-CD3 Market Size by Country (2021-2026)
  8. 8.2.3 Europe Muromonab-CD3 Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Muromonab-CD3 Sales by Country
  2. 9.1.1 Asia-Pacific Muromonab-CD3 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Muromonab-CD3 Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Muromonab-CD3 Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Muromonab-CD3 Market Size by Country
  6. 9.2.1 Asia-Pacific Muromonab-CD3 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Muromonab-CD3 Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Muromonab-CD3 Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Muromonab-CD3 Sales by Country
  2. 10.1.1 South America Muromonab-CD3 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Muromonab-CD3 Sales by Country (2021-2026)
  4. 10.1.3 South America Muromonab-CD3 Sales Forecast by Country (2027-2032)
  5. 10.2 South America Muromonab-CD3 Market Size by Country
  6. 10.2.1 South America Muromonab-CD3 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Muromonab-CD3 Market Size by Country (2021-2026)
  8. 10.2.3 South America Muromonab-CD3 Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Muromonab-CD3 Sales by Country
  2. 11.1.1 Middle East and Africa Muromonab-CD3 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Muromonab-CD3 Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Muromonab-CD3 Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Muromonab-CD3 Market Size by Country
  6. 11.2.1 Middle East and Africa Muromonab-CD3 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Muromonab-CD3 Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Muromonab-CD3 Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Muromonab-CD3 Value Chain Analysis
  2. 12.1.1 Muromonab-CD3 Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Muromonab-CD3 Production Mode & Process
  7. 12.2 Muromonab-CD3 Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Muromonab-CD3 Distributors
  10. 12.2.3 Muromonab-CD3 Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst